RhumbLine Advisers
ELOX

RhumbLine Advisers’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History

RhumbLine Advisers’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-744
Closed -$99K – 3156
2021
Q1 		$99K Sell
744
-90
-11% -$13.8K ﹤0.01% 2934
2020
Q4 		$133K Buy
834
+139
+20% +$17K ﹤0.01% 2929
2020
Q3 		$73K Sell
695
-150
-18% -$18K ﹤0.01% 2923
2020
Q2 		$102K Buy
845
+91
+12% +$10.3K ﹤0.01% 2963
2020
Q1 		$59K Sell
754
-8
-1% -$1.3K ﹤0.01% 2846
2019
Q4 		$224K Buy
762
+7
+0.9% +$1.41K ﹤0.01% 2714
2019
Q3 		$136K Buy
755
+20
+3% +$5.69K ﹤0.01% 2836
2019
Q2 		$293K Buy
735
+43
+6% +$18.1K ﹤0.01% 2620
2019
Q1 		$323K Sell
692
-22
-3% -$10.7K ﹤0.01% 2502
2018
Q4 		$343K Buy
714
+243
+52% +$134K ﹤0.01% 2471
2018
Q3 		$321K Sell
471
-23
-5% -$14.7K ﹤0.01% 2480
2018
Q2 		$337K Buy
+494
New +$320K ﹤0.01% 2475

Other funds holding ELOX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

RhumbLine Advisers's ELOX Position: Q2 2021 in Review

RhumbLine Advisers sold out of Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) in Q2 2021, closing a stake of 744 shares — an estimated $99K sold.

RhumbLine Advisers first reported a position in ELOX in Q2 2018 and held it in 12 quarters. The position peaked at $343K in Q4 2018. 46 funds tracked by Wall St. Rank hold ELOX as of Q2 2021.

  • RhumbLine Advisers reported no remaining Eloxx Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 744 Eloxx Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $99K.
  • RhumbLine Advisers first reported a position in Eloxx Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 12 quarters.
  • RhumbLine Advisers's Eloxx Pharmaceuticals, Inc. Common Stock position peaked at $343K in Q4 2018.
  • 46 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.